Article Text

Download PDFPDF

1115 RAIL biomarkers capture response to induction therapy in pediatric patients during induction therapy
  1. Ellen M Cody1,
  2. Scott Wenderfer2,
  3. Kathleen Sullivan3,
  4. Alfred Kim4,
  5. Tingting Qiu5,
  6. Bin Huang5,6,
  7. Prasad Devarajan1,6 and
  8. Hermine I Brunner6,7
  1. 1Cincinnati Children’s Hospital Medical Center Division of Nephrology and Hypertension
  2. 2BC Children’s Hospital, Division of Nephrology
  3. 3Children’s Hospital of Philadelphia Division of Allergy and Immunology
  4. 4Washington University in St. Louis, Division of Rheumatology
  5. 5Cincinnati Children’s Hospital Medical Center, Division of Epidemiology and Biostatistics
  6. 6University of Cincinnati, Department of Pediatrics
  7. 7Cincinnati Children’s Hospital Division of Rheumatology


Background Systemic Lupus Erythematosus (SLE) remains a diagnostic and therapeutic challenge, particularly lupus nephritis (LN). We previously described a composite score, the pediatric Renal Activity Index for Lupus (pRAIL), consisting of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), monocyte chemotactic protein 1 (MCP-1), adiponectin, hemopexin and ceruloplasmin, where higher scores represent more active inflammation on biopsy. We hypothesized that when followed longitudinally during induction therapy, pRAIL significantly improves during induction therapy in complete responders, and aimed to assess the difference between complete and partial responders.

Methods Patients aged 23 and younger diagnosed with LN were recruited (IRB #2008-0635). Diagnosis was made according to ACR criteria for SLE, with renal biopsy confirmation of LN. Urine was collected at diagnosis and end of induction. Complete responders were defined by urine protein to creatinine ratio <0.5 mg/mg, absence of hematuria, and normal glomerular filtration rate.

Partial responders had decrease in proteinuria by 50% and GFR stable to improved from diagnosis. Response was also defined as improved activity index on follow up biopsy.

Descriptive analyses, ANOVA, paired and student t-tests were performed for analyses.

Results A total of 25 patients aged 23 or younger were recruited at the start of induction therapy. 15 of the patients were complete responders, 7 were partial responders. Table 1 shows the characteristics and pRAIL scores of the complete and partial responders pre and post therapy. Among the three non-responders, standardized and non-standardized pRAIL scores numerically increased during induction therapy. The mean±SD of pRAIL scores significantly decreased in complete responders by 1.07 ± 1.7 (p=0.03) and were unchanged in partial responders (0.07 ± 1.56, p= 0.91), as shown in figure 1.

Conclusions This study shows the pRAIL score (both absolute and standardized) distinguishes complete responders versus partial responders during induction therapy. Complete responders pRAIL score decrease by mean of 1 point, whereas partial responders had no change. Notably, standardized pRAIL scores yielded more pronounced differences during induction therapy among both partial and complete responders.

Abstract 1115 Table 1

Characteristics and Biomarkers of Complete, Partial and Non-Responders in Pediatric Patients during Induction Therapy

Abstract 1115 Figure 1

Change in pRAIL score by clinical response status

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: .

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.